CSPC Pharmaceutical Group (HK:1093) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CSPC Pharmaceutical Group reported a 4.9% decline in total revenue for the first nine months of 2024, driven by decreases in its finished drug and bulk product sectors. The company’s underlying profit attributable to shareholders fell by 15.2%, attributed to reduced sales in key therapeutic areas like oncology, despite growth in newer products. This financial dip reflects the challenges faced amid tightened hospital controls and significant price cuts from volume-based procurement initiatives.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.